Telix Pharmaceuticals (NASDAQ:TLX) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Telix Pharmaceuticals from a "hold" to a sell, even though the consensus analyst rating remains a Moderate Buy with an average price target of $21.13.
• Shares trade around $7.85 (52-week range $6.28–$20.00) and the company missed quarterly earnings, reporting EPS of ($0.01) versus the $0.05 consensus.
• Several institutional investors have increased or initiated positions recently, including Portland Investment Counsel (+108%), Lazard Asset Management (+118.6%), and new stakes from Millennium Management and Russell Investments.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday.

TLX has been the topic of a number of other reports. Citigroup raised their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a "buy" rating in a research report on Tuesday, February 24th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, January 19th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $21.13.

Telix Pharmaceuticals Stock Down 0.5%

TLX opened at $7.85 on Friday. The firm has a 50 day simple moving average of $7.32 and a 200 day simple moving average of $8.80. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $20.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last released its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). Equities research analysts anticipate that Telix Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Large investors have recently modified their holdings of the business. Portland Investment Counsel Inc. raised its holdings in shares of Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company's stock worth $2,063,000 after buying an additional 138,200 shares in the last quarter. Lazard Asset Management LLC boosted its stake in Telix Pharmaceuticals by 118.6% in the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company's stock valued at $1,876,000 after buying an additional 135,893 shares in the last quarter. Millennium Management LLC bought a new position in Telix Pharmaceuticals in the third quarter valued at about $1,883,000. Russell Investments Group Ltd. acquired a new position in Telix Pharmaceuticals during the second quarter worth about $975,000. Finally, Private Advisor Group LLC raised its stake in Telix Pharmaceuticals by 67.3% during the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company's stock worth $403,000 after acquiring an additional 16,945 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.